[Chronic pulmonary heart diseases treated by fraxiparin].
OBJECTIVE
The effects of fraxiparine with hypodermic on the treatment of patients with chronic pulmonary heart diseases(CPHD) at acute phase were studied.


METHODS
Twenty patients were hypodermically injected with 0.4 ml fraxiparine per day for 7 days as a course. Fibrin fibrinogen degradation products (FDP and D-dimer), antithrombin III (AT-III), PaO2 and PaCO2 were detected before and after the treatment.


RESULTS
In the therapy group, FDP and D-dimer decreased after the treatment, AT-III increased. All indexes didn't alter in the control group.


CONCLUSIONS
Fraxiparine is effective on patients with CPHD at acute phase.
Duan
S
S
Department of Internal Medicine, Second Affiliated Hospital, Hunan Medical University, Changsha.
Wu
S
S
Chen
P
P
D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D000990:Antithrombin III / Q000378:metabolism; D002908:Chronic Disease; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D006801:Humans; D008297:Male; D017762:Nadroparin / Q000627:therapeutic use*; D011660:Pulmonary Heart Disease / Q000188:drug therapy*
D000925:Anticoagulants; D005338:Fibrin Fibrinogen Degradation Products; D017762:Nadroparin; D000990:Antithrombin III